IIS

Vishakha RM Honored With 2024 IIS Vanguard Award

Retrieved on: 
Dienstag, Mai 14, 2024
Insurance, Professional Services, Science, Business Today, Vishākhā, Woman, ASSOCHAM, Sale, Group insurance, Publication, IIS, MD, Growth, BFSI, Social media, Pension, CII, National Committee, Multimedia, Management

The International Insurance Society (IIS) has named Vishakha RM, MD and CEO of IndiaFirst Life Insurance , the Vanguard Market Development Award 2024 honoree.

Key Points: 
  • The International Insurance Society (IIS) has named Vishakha RM, MD and CEO of IndiaFirst Life Insurance , the Vanguard Market Development Award 2024 honoree.
  • Vishakha will be formally honored at an awards ceremony on Nov. 17, 2024, at the Hyatt Regency Miami.
  • View the full release here: https://www.businesswire.com/news/home/20240514453164/en/
    Vishakha RM, MD and CEO, IndiaFirst Life Insurance, is the Vanguard Market Development Award 2024 honoree from the International Insurance Society.
  • In addition to the Vanguard Market Development Award, Vishakha has been honored with the Individual Achievement Award by ASSOCHAM and the CA Business Leader - Woman Award by the Institute of Chartered Accountants of India.

Gainwell Recognized for Healthcare Data Innovation in 2024 MedTech Breakthrough Awards Program

Retrieved on: 
Donnerstag, Mai 9, 2024
Immunization, Medtech, Public, Health equity, IIS, Health, Artificial intelligence, Patient, Vaccine-preventable diseases, Vaccine

IRVING, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Gainwell Technologies (Gainwell), a leading innovator in healthcare technology solutions, today announced that its modernized Immunization Information System (IIS) won the “Best Healthcare Data Repository Solution” award in the eighth annual MedTech Breakthrough Awards program.

Key Points: 
  • IRVING, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Gainwell Technologies (Gainwell), a leading innovator in healthcare technology solutions, today announced that its modernized Immunization Information System (IIS) won the “Best Healthcare Data Repository Solution” award in the eighth annual MedTech Breakthrough Awards program.
  • MedTech Breakthrough is an independent market intelligence organization recognizing the top companies, technologies, and products in the global digital health and medical technology market.
  • Gainwell’s real-time population data helps organizations meet public health needs with greater responsiveness and preparedness,” said Steve Johansson, managing director, MedTech Breakthrough.
  • “Gainwell unlocks the true power of immunization systems, providing benefits in public health, health equity, and cost containment.”
    The MedTech Breakthrough Awards honor excellence and recognize the innovation, hard work, and success in a range of health and medical technology categories.

ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2024

Retrieved on: 
Montag, Mai 6, 2024
Charcot–Marie–Tooth disease, FDA, Venetoclax, OHSU, Innovation, National Cancer Institute, BPD, Development, IND, CNS, NET, Schizophrenia, EVOLUTION, JHU, Azacitidine, NCI, FCCC, Deficit spending, IP, Paclitaxel, IIS, Food, European Patent Convention, CMT, Borderline personality disorder, Communication, Conference, AML, Aggression, Convertible bond, FMS, ALS, Phase, Kabuki syndrome, HOPE, Safety, SCLC, DSM-IV codes, EMA, Clinical trial, Medicine, EPO, Investigational New Drug, Duration, Platinum, Bangladesh Technical Education Board, Phase II, MRD, ICIS, MSKCC, Disease, Measure (mathematics), CRADA, Dor, Patent, HDAC6, Data analysis, Genomics, Pharmaceutical industry

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the first quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the first quarter.
  • Research and development (R&D) expenses were $2.6 million for the quarter ended March 31, 2024, compared to $4.4 million for the quarter ended March 31, 2023.
  • General and administrative expenses were $0.9 million for the quarter ended March 31, 2024, compared to $1.2 million for the quarter ended March 31, 2023.
  • Net losses were $1.1 for the quarter ended March 31, 2024, respectively, compared to $1.4 million for the quarter ended March 31, 2023.

Maiden Holdings, Ltd. Announces Renewal Rights Transaction for International Primary Business

Retrieved on: 
Montag, Mai 6, 2024
Asset Management, Professional Services, Insurance, Finance, AmTrust Financial Services, IIS, AmTrust Bank, Holding, Auction

Maiden Holdings, Ltd. (NASDAQ: MHLD) (“Maiden”) today announced it had entered into a renewal rights transaction with AmTrust Nordic AB, a Swedish unit of AmTrust Financial Services, Inc. (“AmTrust”).

Key Points: 
  • Maiden Holdings, Ltd. (NASDAQ: MHLD) (“Maiden”) today announced it had entered into a renewal rights transaction with AmTrust Nordic AB, a Swedish unit of AmTrust Financial Services, Inc. (“AmTrust”).
  • The transaction is expected to cover the majority of its primary business written through its Swedish subsidiaries, Maiden General Försäkrings (“Maiden GF”) and Maiden Life Försäkrings (“Maiden LF”) in Sweden, Norway and other Nordic countries.
  • Maiden also reported that it anticipates entering into additional renewal rights agreements with other AmTrust entities for certain business written by Maiden GF and Maiden LF in the United Kingdom and Ireland.
  • As part of these conclusions, Maiden expects to enter into additional transactions to either sell or wind-up Maiden GF and Maiden LF during 2024 and is actively evaluating potential transactions currently.

Iapetus Infrastructure Services Welcomes Brian Sprinkle as Director of UVM Consulting and Innovation

Retrieved on: 
Mittwoch, Mai 8, 2024
Sprinkle, SCE, Innovation, Distribution, GIS, Knowledge, IIS, UVM, Consultant

HOUSTON, May 8, 2024 /PRNewswire/ -- Iapetus Infrastructure Services (IIS), an independent utility infrastructure services firm, continues to bolster its consulting services by adding experienced utility vegetation management (UVM) leader Brian Sprinkle as Director of UVM Consulting and Innovation.

Key Points: 
  • HOUSTON, May 8, 2024 /PRNewswire/ -- Iapetus Infrastructure Services (IIS), an independent utility infrastructure services firm, continues to bolster its consulting services by adding experienced utility vegetation management (UVM) leader Brian Sprinkle as Director of UVM Consulting and Innovation.
  • Sprinkle joins IIS' expanding team of industry experts, which now also includes Director of UVM Development Adam Warf and trusted UVM veterans Phil Charlton, Steve Hallmark, and Tom Sullivan.
  • "I'm thrilled to be joining this esteemed group of UVM leaders whose expertise and dedication are renowned in our field," Sprinkle proclaims.
  • "Together, we look forward to driving innovation and continued excellence to our clients and shaping the future of our industry."

Prem Watsa Named 2024 Insurance Hall of Fame Laureate

Retrieved on: 
Donnerstag, April 18, 2024
Professional Services, Insurance, Human Resources, Education, Watsa, University, RGA, IIS, Canada Dry, Hospital for Sick Children, Principal Financial Group, Entrepreneurship, Fairfax Financial, Toronto Stock Exchange, Acquisition, Chemical engineering, Fame, Multimedia, MBA, Padma Shri, Confederation Life, Management

The International Insurance Society (IIS) has named Prem Watsa, the Founder, Chairman and CEO of Toronto-based Fairfax Financial Holdings Limited , the 2024 Insurance Hall of Fame Laureate.

Key Points: 
  • The International Insurance Society (IIS) has named Prem Watsa, the Founder, Chairman and CEO of Toronto-based Fairfax Financial Holdings Limited , the 2024 Insurance Hall of Fame Laureate.
  • View the full release here: https://www.businesswire.com/news/home/20240418306017/en/
    Prem Watsa, the Founder, Chairman and CEO of Toronto-based Fairfax Financial Holdings Limited, has been named the 2024 Insurance Hall of Fame Laureate by the International Insurance Society.
  • (Photo: Business Wire)
    The Insurance Hall of Fame recognizes leaders who have made a broad, encompassing, and lasting contribution to the insurance industry.
  • “As the 2024 Insurance Hall of Fame Laureate, Mr. Prem Watsa's legacy of excellence, ingenuity and integrity continues to inspire future generations in the insurance industry and beyond,” says Josh Landau, President of the International Insurance Society.

Save the Date: Triple-I and International Insurance Society Team Up for Week of Transformative Discussions in Miami in November

Retrieved on: 
Mittwoch, März 20, 2024
Insurance, Professional Services, Risk management, Insurance Information Institute, IIS, Government, The Institutes

They’ll discuss what’s working, what challenges persist, and how best to move forward in an evolving risk environment.

Key Points: 
  • They’ll discuss what’s working, what challenges persist, and how best to move forward in an evolving risk environment.
  • IIS’ theme is Illuminating Insurance Innovation, which will focus on the impact of innovation on the insurance value chain.
  • “The industry is undergoing rapid transformation fueled by innovation,” said Joshua Landau, president of IIS.
  • Registration will open in the spring.

Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024

Retrieved on: 
Freitag, März 8, 2024
Assay, Cancer, JNK, NLRP3, AACR, IIS, Biochemistry, Cellular, Therapy, Reactive oxygen species, Tumor microenvironment, Patient, ROS, Research, Pharmaceutical industry

“The ability to impact multiple targets is an important characteristic of Onconova’s two lead clinical programs, rigosertib and narazaciclib.

Key Points: 
  • “The ability to impact multiple targets is an important characteristic of Onconova’s two lead clinical programs, rigosertib and narazaciclib.
  • We are pleased to present new preclinical studies that explore the molecular targets for rigosertib, in clinical development through a series of investigator initiated studies (IIS),” commented Steven Fruchtman, M.D., President and Chief Executive Officer of Onconova.
  • “The studies provide additional prospective on the main cellular pathways impacted by rigosertib, including RAS-MAPK signaling and reactive oxygen species (ROS)-related proteins.
  • Conclusions: This work identified a series of cellular and inflammatory targets that may be affected by rigosertib.

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023

Retrieved on: 
Montag, Februar 26, 2024
Borderline personality disorder, HOPE, HDAC6, National Cancer Institute, EVOLUTION, CMT, Agitation, Data analysis, Convertible bond, ICIS, ALS, SCLC, Azacitidine, Duration, ICI, IIS, Sciatic nerve, Deficit spending, Paclitaxel, DSM-IV codes, Development, Genomics, ALS Association, FMS, LSD1, AML, Clinical Global Impression, MSKCC, Conference, Aggression, Safety, Biomarker, CNS, Venetoclax, CRADA, OHSU, MRD, Clinical trial, BPD, Measure (mathematics), IND, FCCC, Dor, Human, Innovation, EMA, Kabuki syndrome, NET, NCI, Aes, Glomus tumor, FDA, GST, Food, Platinum, Schizophrenia, Phase II, Charcot–Marie–Tooth disease, Medicine, Patient, BEST, Disease, Pharmaceutical industry

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.
  • Research and development (R&D) expenses were $3.9 and $16.6 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $5.0 and $18.1 million for the quarter and twelve months ended December 31, 2022.
  • General and administrative expenses were $1.2 and $4.2 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.2 and $4.8 million for the quarter and twelve months ended December 31, 2022.
  • Net losses were $1.4 and $5.0 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.6 and $5.9 million for the quarter and twelve months ended December 31, 2022.

Pioneering Technique Reveals New Layer of Human Gene Regulation

Retrieved on: 
Freitag, Februar 9, 2024
Human, NYU Langone Health, RNA, Chromatin, Tick, Cell division, Cancer, Howard Hughes Medical Institute, IIS, DNA repair, Genetic code, Bangladesh Technical Education Board, Protein, NYU, RNA polymerase II, Multimedia, DNA, Genome, Biochemistry, Gene expression, Pharmacology, Gene, Bacteria, National Institutes of Health, Ageing, Doctor of Philosophy, Disease, Vaccine

Now a new study led by Nudler's team at NYU Langone Health reveals that their new technique, Long Range Cleavage sequencing (LORAX-seq), can directly detect where backtracking events begin and end.

Key Points: 
  • Now a new study led by Nudler's team at NYU Langone Health reveals that their new technique, Long Range Cleavage sequencing (LORAX-seq), can directly detect where backtracking events begin and end.
  • The results also suggest that persistent backtracking occurs frequently throughout genomes, happens more often near certain gene types, and has functions well beyond DNA repair.
  • "If further work expands our findings to different developmental programs and pathological conditions, backtracking may be akin to epigenetics, the discovery of which revealed a surprising new layer of gene regulation without changing the DNA code."
  • Locked, backtracked complexes are less likely to be rescued by TFIIS-driven cleavage, and more likely to delay transcription of the gene involved.